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Regulation of the proapoptotic functions of prostate
apoptosis response-4 (Par-4) by casein kinase 2 in
prostate cancer cells
A de Thonel*,1,2,16, A Hazoumé1,2,16, V Kochin3, K Isoniemi4,5, G Jego1,2, E Fourmaux1,2, A Hammann1,2, H Mjahed1,2, O Filhol6,
O Micheau1,2, P Rocchi7,8, V Mezger9,10, JE Eriksson4,5, VM Rangnekar11,12,13,14 and C Garrido*,1,2,15

The proapoptotic protein, prostate apoptosis response-4 (Par-4), acts as a tumor suppressor in prostate cancer cells. The serine/
threonine kinase casein kinase 2 (CK2) has a well-reported role in prostate cancer resistance to apoptotic agents or anticancer
drugs. However, the mechanistic understanding on how CK2 supports survival is far from complete. In this work, we
demonstrate both in rat and humans that (i) Par-4 is a new substrate of the survival kinase CK2 and (ii) phosphorylation by CK2
impairs Par-4 proapoptotic functions. We also unravel different levels of CK2-dependent regulation of Par-4 between species. In
rats, the phosphorylation by CK2 at the major site, S124, prevents caspase-mediated Par-4 cleavage (D123) and consequently
impairs the proapoptotic function of Par-4. In humans, CK2 strongly impairs the apoptotic properties of Par-4, independently of
the caspase-mediated cleavage of Par-4 (D131), by triggering the phosphorylation at residue S231. Furthermore, we show that
human Par-4 residue S231 is highly phosphorylated in prostate cancer cells as compared with their normal counterparts. Finally,
the sensitivity of prostate cancer cells to apoptosis by CK2 knockdown is significantly reversed by parallel knockdown of Par-4.
Thus, Par-4 seems a critical target of CK2 that could be exploited for the development of new anticancer drugs.
Cell Death and Disease (2014) 5, e1016; doi:10.1038/cddis.2013.532; published online 23 January 2014
Subject Category: Cancer

Prostate apoptotis response-4 (Par-4) is a ubiquitously
expressed protein characterized by its ability to induce
apoptosis in cancer cells only but not in normal or immortalized cells.1–3 The proapoptotic role of Par-4 was first
discovered in rat prostate cancer cells undergoing apoptosis
in response to calcium inducers. The essential role of Par-4 in
apoptosis was later confirmed in diverse cell types in
response to cellular insults, such as ultraviolet, cytokines,
serum withdrawal, hormone deprivation and exposure to
cytotoxic drugs.4–6 Consistent with an important role of Par-4
in apoptosis, ectopic expression of Par-4 in various cultured
cells, including NIH3T3 cells, neurons, melanoma, prostate
and colon cancer cells, has been found to sensitize these cells
to apoptotic stimuli or chemotherapeutic drugs.7–11 In
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addition, the in vivo delivery of Par-4 plasmid by nanoliposomes or Par-4 adenovirus injection into tumors growing in
nude mice (HT29 and PC-3 cells, respectively) induces tumor
regression1 and/or tumor sensitization to therapeutic
agents.12
The par-4 gene maps to human chromosome 12q21, in a
region often deleted in pancreatic and gastric cancers, as well
as in tumors of male germ cell.13,14 In addition, Par-4 is
downregulated in many cancers, including breast cancer,15
lymphoma,16 renal and pancreatic carcinoma.17 Most important, Par-4 was recently described as a major determinant
underlying breast cancer recurrence, and its reduced expression was associated with poor prognosis.15,18 Oncogenes like
Ras, Raf or Src are involved in the reduction of Par-4
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abundance, and restoration of Par-4 levels in those models
leads to tumor cell apoptosis.3,19 Notably, Par-4 null mice
develop spontaneous tumors in the prostate, endometrium,
liver or lungs or carcinogen-induced tumors in the bladder and
endometrium, providing strong evidence of Par-4’s tumorsuppressor activity.20
Functionally, the critical domains of Par-4 include the
C-terminus leucine zipper domain, which mediates interaction
with its partners (e.g., Wilm’s tumor suppressor, atypical
protein kinase C (PKCz), ZIP kinase) and the core domain
designated SAC (selective for apoptosis in cancer cells,
spanning amino acids 137–195), which is essential for Par-4
apoptotic function.21 Human Par-4 can be cleaved by
caspases at the D131 site and the generated C-terminus
cleaved form (132–340 aa) includes the fully active SAC
domain.22–24 The proapoptotic properties of Par-4 depend on
both caspase activation and inhibition of survival factors,
including nuclear factor kappa B (NF-kB),8,11 PKCz7 and/or
Akt kinase.25 Par-4 is also spontaneously secreted from
mammalian cells via the classical endoplasmic reticulum
(ER)-Golgi pathway.26 Following secretion, Par-4 is able to
induce apoptosis both in vitro and in vivo through the
activation of the 78-kDa glucose-regulated protein receptor/
caspases pathway.26,27 Par-4 functions are regulated by
different kinases, including Akt and protein kinase A (PKA).
Akt induces Par-4 phosphorylation and this triggers its binding
and sequestration in the cytoplasm by the chaperone proteins
14–3–3, thus preventing apoptosis in prostate cancer cells.28
In contrast, PKA phosphorylates Par-4 (on residue T155 in rat
Par-4 and T163 in human Par-4) to activate the proapoptotic
functions of Par-4.29
Casein kinase 2 (CK2) is a constitutive, highly conserved
serine/threonine kinase that recognizes the acidic consensus
motif ‘S/T-X-X-Asp/Glu/pSer’ (X denotes any non-basic
amino acid).30,31 Generally, CK2 acts as a tetrameric
holoenzyme, which comprises two catalytic (CK2a) and two
regulatory (CK2b) subunits. CK2b mediates interactions
between the catalytic subunits and many of its substrates,
thereby modulating substrate selectivity and catalytic activity.30,31
The activity and/or expression of CK2 has been found to be
significantly enhanced in many human cancers, including
prostate, head and neck, colon and lung32–35 as well as in
experimental rodent tumors.36 Although the mechanistic
understanding of how CK2 exerts its protective role on cell
survival remains far from complete, increasing evidence links
CK2 to the dual function of pro-survival and apoptotic
pathways. Indeed, CK2 has been reported to support, on
the one hand, cell viability via activation of Wnt, Akt and NF-kB
signaling pathways and, on the other hand, apoptosis by: (i)
protecting some proapoptotic proteins from caspasemediated degradation and (ii) inhibiting the mitochondrial
pathway.37–39 The anti-apoptotic function of CK2 is further
supported by the fact that inhibitors of CK2 enhance the
susceptibility of cancer cells to apoptosis induced by death
receptors (such as tumor necrosis factor (TNF-a), TNFrelated apoptosis-inducing ligand (TRAIL) and Fas Ligand) or
drugs (such as etoposide, diethylstilbestrol, resveratrol).
Conversely, increased activity and/or expression of CK2,
observed in cancer cells, including prostate cancer cells,
protects from cell death induced by cytotoxic insults.9,40–44
Cell Death and Disease

Par-4 and CK2 activities have opposing effects
on apoptosis and tumor growth, particularly in prostate
cancer.9,6,18,28,39,45 Given that Par-4 sequence analysis
revealed potential sites for CK2 phosphorylation
that are overall evolutionarily conserved (database http://
scansite.mit.edu), we hypothesized that Par-4 could be a
target of CK2. We demonstrate, both in human and rodents,
that CK2 directly associates with and phosphorylates
Par-4. We also show that the phosphorylation by CK2 of
S231 in human Par-4 and S124/S223 in rodent Par-4 inhibits
the proapoptotic functions of Par-4. Furthermore, our
results underline a species-dependent regulation of Par-4
cleavage through phosphorylation by CK2 at residue
S124 of rodent Par-4.
Importantly, a higher phosphorylation of the human Par-4
residue S231 was observed in prostate cancer cells – which
display elevated CK2 activity – compared with their normal
counterparts. Finally, we showed that the anti-apoptotic effect
of CK2 in human prostate cancer cells depends on Par-4
inhibition, thereby identifying Par-4 as a functionally critical
substrate of CK2.

Results
Both human and rodent Par-4 are new substrates of
CK2. To study whether Par-4 is a target of CK2, we first
assessed the ability of Par-4 to interact with CK2 subunits
both in human and rodent cells. Given the extremely high
homology between human and rodent CK2, we used human
CK2 for all our experiments. Rat green fluorescent protein
(GFP)-Par-4 and the hemagglutinin (HA)-tag CK2 subunits
(CK2a and/or CK2b) were co-transfected in COS cells and
immunoprecipitated either with anti-GFP (Par-4) or anti-HA
(CK2 subunit) antibodies. As commonly noted with other CK2
substrates,30 Par-4 was co-immunoprecipitated with the a
subunit of CK2 but not with the GFP-tag (Figure 1a, left
panels). We further evaluated the ability of Par-4 to coimmunoprecipitate with the CK2b subunit (Figure 1a, right
panels). As shown in Figure 1a (upper right panel), we did not
detect any interaction between Par-4 and the CK2b subunit,
whereas Par-4 co-immunoprecipitated with the CK2 holoenzyme. We next examined the ability of endogenous human
Par-4 to associate with CK2. Similar to rat GFP-Par-4,
human Par-4 interacts with the a subunit of the CK2
holoenzyme but not with the CK2b subunit (Figure 1b). To
determine whether the interaction was direct,35 S-labeled
subunit CK2a and/or CK2b were incubated with rat
glutathione-S-transferase (GST)-Par-4 or GST alone, and
immunoprecipitation was performed using an anti-GST
antibody (Supplementary Figure S1a). The resolution of the
immunoprecipitated complexes in sodium dodecyl phosphate
polyacrylamide gel electrophoresis (SDS-PAGE) confirmed
that Par-4 interacts directly with CK2.
Next, we determined whether Par-4 could be phosphorylated by CK2 both in human and rodent cells. We performed
an in vitro kinase assay, using either the immunoprecipitated
GFP-tag CK2a and CK2b subunits in the presence
of rat GST-Par-4 (Figure 1c) or the recombinant CK2 in
presence of human GFP-Par-4 as a substrate (Figure 1d).
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Figure 1 Both rodent and human Par-4 interact and are substrates of CK2. (a) COS cells were co-transfected with rat GFP-tagged Par-4 or empty GFP vector together
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recombinant CK2b (32P- CK2b) was detected by autoradiography. The amount of recombinant GFP-Par-4 produced by RRL was checked by western blotting (input, lower
panel)

These experiments indicate that CK2 phosphorylates Par-4
(Figures 1c and d). As for the majority of CK2 substrates, the
presence of the regulatory subunit CK2b was necessary to
phosphorylate Par-4 as judged by the effect of increasing
doses of CK2b on Par-4 phosphorylation (Supplementary

Figure S1b). As Par-4 functions are regulated by phosphorylation,28,29 we searched for a phosphatase able to dephosphorylate Par-4. By means of phosphatase inhibitors and the
use of recombinant protein phosphatase 1 (PP1), we
observed that phosphatase PP1 interacts with and leads to
Cell Death and Disease
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an efficient dephosphorylation of Par-4 (Supplementary
Figure S2 and Supplementary Data). Accordingly, the
phosphatase PP1 has been shown to dephosphorylate
several substrates of CK2.46
Collectively, the fully active holoenzyme CK2 phosphorylates human and rodent Par-4, and this action might be
counteracted by PP1 phosphatases.
Phosphorylation of rodent Par-4 by CK2 and
consequences on its proapoptotic functions. In order
to characterize the CK2 target site(s), we performed a tryptic
phosphopeptide map of rat Par-4-GST phosphorylated in vitro
with recombinant CK2 (in vitro kinase assay done as in
Figure 1c). Autoradiography of the thin layer chromatography
(TLC)-plate with the tryptic peptides separated in two
dimensions indicates that the in vitro 32P-labeled material
has three major CK2-specific spots designated phosphopeptides P1, P0 1 and P2 (Figure 2a). MS analysis of these
major phosphopeptides (Table 1, spectra shown in
Supplementary Figure S3a) allowed identification of the
following phosphopeptides P1: 117-GDEEEPDpS(124)
APEK-128, P’1: 117-GDEEEPDpS(124)APEKGR-128 and
P2: 220-STIpS(223)APEEEILNRYPR-235. Matrix-assisted
laser desorption/ionization-time-of-flight-mass spectrometry
(MALDI-TOF-MS) analysis indicated that the P10 phosphopeptide was similar to P1 but lacked a cryptic cleavage site at
the C-terminus. The identity of the CK2-specific phosphopeptides P1, P0 1 and P2 was further checked by manual Edman
degradation (Supplementary Figure S3b). Accordingly, S124
and S223 residues of rat Par-4 were the targeted sites of CK2.
In order to determine the functional relevance of rat Par-4
phosphorylation by CK2, we constructed two GFP-tagged
mutants of Par-4 in which the two serine residues were
substituted either by alanine (124A223A) or by aspartic acid
(124D223D) that prevent or mimic phosphorylation, respectively. An in vitro kinase assay with the 124A223A mutant
confirmed that CK2 was no longer able to induce Par-4
phosphorylation (Figure 2b). Moreover, we observed a
decrease in the phosphorylation, with the single mutant
124D or 223D (Supplementary Figure S3c).
Par-4 is known to inhibit the cell survival pathways like the
NF-kB pathway and to induce apoptosis in a caspasedependent manner. In contrast, CK2 has been reported to
stimulate the transcriptional activity of NF-kB and to prevent
caspase activation.39,40 We therefore investigated the effect
of the two phosphomutants on the proapoptotic functions of
Par-4, including the ability to inhibit NF-kB pro-survival
pathway.1,3 Using a luciferase reporter assay, we found that
the 124A223A mutant Par-4 (mimicking the non-phosphorylated Par-4) as well as wild-type Par-4 retained the ability to
inhibit NF-kB transcriptional activity, while the 124D223D
(mimicking the phosphorylated Par-4) lost this capacity
(Supplementary Figure S4).
A similar loss of function for 124D223D was observed when
we studied Par-4 proapoptotic role. Prostate cancer cells
PC-3 were treated either with the death ligand, TRAIL
(Figures 3a–c) or the chemotherapeutic drug, Paclitaxel
(Figure 3d). We found that cells transfected with wild-type
Par-4 or the 124A223A mutant were sensitive to apoptosis
while the cells expressing the 124D223D mutant were still
Cell Death and Disease

resistant (as judged by Hoechst staining, caspase-3, poly
ADP ribose polymerase (PARP) and caspase-8 activation;
Figures 3a–c). Interestingly, we noticed the appearance of a
cleaved form of Par-4 in cells expressing 124A223A or wildtype Par-4 but not in cells expressing 124D223D (Figures 3c
and d). This smaller Par-4 form, 50 kDa in size including GFP,
most likely corresponds to the caspase-induced cleavage
product of Par-4. Indeed, a Par-4 cleaved form was previously
reported in human cells during Fas- or cisplatin-induced
apoptosis.23,24 Thus, phosphorylation by CK2 on residues
S124 and S223 results in loss of rat Par-4 proapoptotic
properties and prevents the generation of the caspasemediated cleaved form of Par-4.
Protective role of CK2-induced phosphorylation of S124
by preventing the caspase-mediated cleavage of Par-4.
We noticed that the rodent Par-4 site S124 is the most
strongly CK2 phosphorylated site (Figure 2a, phosphopeptides P1 and P10 versus P2), and it is in the vicinity of D123,
the ortholog for human D131 that corresponds to the human
caspase cleavage site24 (Supplementary Figures S5a and b).
As the Par-4 cleavage product observed in cells transfected
with Par-4 wild type (Figures 3c and d) disappeared with the
Par-4 mutant D124, we wondered whether CK2 phosphorylation on S124 in rodents could impair caspase-3-mediated
Par-4 cleavage. To test this hypothesis, we first verified that
rodent Par-4 is also cleaved by caspases after an apoptotic
stimulus (Figure 4a). We show that (i) benzyloxycarbonylvalyl-alanyl-aspartic
acid
(O-methyl)-fluoro-methylketone
(zVAD-FMK), a pan inhibitor of caspases, prevents rat
Par-4 cleavage, (ii) the Par-4 mutant D123A (potential
rat caspase site) was not cleavable (Supplementary Figure
S6a, left panel). As previously reported for the Par-4 mutant
D131A human (human caspase site24), mutant D123A also
impaired rat Par-4 proapoptotic function (Supplementary
Figure S6a, right panel, and 6b).
We then examined whether Par-4 cleavage was regulated
by phosphorylation of S124 by CK2. We first performed
an in vitro caspase assay using purified wild-type Par-4 or
its mutants (S124A, S124D, S223A, S223D, S124A,
S223A or S124D/S223D) in the presence of recombinant
caspases. We observed that caspase-3 and caspase-8
cleaved wild-type Par-4 and the mutants S124A and
S124A/S223A, whereas they were unable to cleave
Par-4 mutant S124D and S124D/S223D (Figure 4b and
data not shown). Notably, mutation of rat Par-4 S223 did not
by itself affect caspase cleavage (Figure 4b). Then, to
confirm that loss of Par-4 cleavage was a direct
consequence of CK2 phosphorylation and not an artifact
introduced by the mutation, we performed an in vitro kinase
assay on rat GST-Par-4 using recombinant CK2, followed
by an in vitro caspase assay using recombinant caspase 3.
As shown in Figure 4c, phosphorylation of Par-4 by
CK2 prevented its cleavage by caspase-3, but this effect
was specific to rodent Par-4 as phosphorylated human
Par-4 was still cleaved (Supplementary Figure S6c). Finally,
we show that the proapoptotic function of S124D (mimicking
CK2 phosphorylation) like D123A mutants (non-cleavable
caspase site) of rat Par-4 was impaired (Supplementary
Figure S7). Therefore, in rat, phosphorylation by CK2 at
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rodent Par-4. (a) Two-dimensional phosphopeptide map analysis of the
phosphorylated recombinant rat GST-Par-4. GST-Par-4 was phosphorylated by
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Table 1 Amino-acid sequences of Par-4 tryptic phosphopeptides detected
from 2D-PPM of in vitro 32P-labeled Par-4 by MALDI-MS (spots of 32P-peptides
are shown in Figure 2a)

Spot
Peptide
number
sequence
in 2D-PPM

N-terminus– Theoretical
C-terminus
MH þ

P1

117–128

1382.53

1382.21

117–130

1595.64

1595.26

424–439

1954.95

1954.82

P’1
P2

GDEEEPD
pSAPEK
GDEEEPD
pSAPEKGR
STIpSA
PEEEIL
NRYPR

Observed
MH þ

residue S124 inhibits proapoptotic functions of Par-4 by
preventing caspase-mediated Par-4 cleavage (D123),
whereas in human the proteolytic cleavage of Par-4 (D131)
is apparently not dependent on CK2 phosphorylation.

Recently, Chaudhry et al.24 have shown that the caspasecleaved form of human Par-4 displays proapoptotic activity.
Therefore, we tested whether rat Par-4 caspase-cleaved
fragment retained the apoptotic properties of wild-type Par-4.
We found that expression of rat Par-4 (124–332) cleaved form
sensitizes cells to apoptosis induced by TRAIL more
efficiently than wild-type Par-4, as measured by its ability to
induce chromatin condensation, caspase-3 activation and
cleavage of PARP and caspase-8 (Figures 4d–f).
Par-4 is known to be spontaneously secreted by normal and
cancer cells in culture. Once secreted, Par-4 can induce
apoptosis of surrounding cancer cells through the activation of
the caspases’ signaling pathway.26 Therefore, we first
studied whether cleaved Par-4 (124–332) could be secreted.
COS cells were transfected with GFP alone, wild-type GFPPar-4 or Par-4 (124–332), and the presence of those proteins
in the conditioned media was determined by western blotting
analysis. We found both Par-4 and Par-4 (124–332) in
the cell-conditioned media, while GFP alone was not
detectable (Supplementary Figure S8a). To address the
exogenous function of caspase-cleaved Par-4, we added
Par-4 (124–332) or wild-type Par-4 (same volume from the
concentrated conditioned media) into PC-3 cell culture
medium for 24 h, and the rate of apoptosis was evaluated.
As shown in Supplementary Figure S8b, extracellular Par-4
(124–332) exerted a stronger apoptotic effect than wild-type
Par-4. Collectively, these findings indicate that CK2 regulates
the proapoptotic functions of rodent Par-4 by preventing its
caspase-mediated cleavage in a phosphorylation-dependent
manner.
Phosphorylation of human Par-4 S231 site by CK2 and
its protective function. By comparative analysis of human
and rodent Par-4 sequences, we determined the human
phosphosite orthologs of rodents S124 and S223 (Figure 5a,
Supplementary Figure S5). Unlike the phosphosite S124 site
(Supplementary Figure S5b), the corresponding S223
phosphosite, S231 in humans, is well conserved between
species (Figure 5a) and was also detected by mass
spectrometry analysis on leukemia cell lines (www.phosphosite.com), thereby supporting a functional role for this
site.
To determine whether S231 is a target of CK2, we
performed an in vitro kinase assay with recombinant CK2 in
the presence of immunoprecipitated human wild-type Par-4 or
S231D Par-4 mutant produced by in vitro translation. We
found that mutation of the S231 site markedly decreased the
phosphorylation of human Par-4 by CK2, suggesting that
S231 is a target site for CK2 (Figure 5b).
To validate the role of Par-4 phosphorylation in prostate
cancer, we generated an antibody directed against the
phosphoserine 231 residue of human Par-4. We detected
an expected protein band in prostate cancer PC-3 cells
corresponding to phosphorylated Par-4 (Figure 5c). This band
was not detectable when the blocking peptide was added,
showing the specificity of the anti-phospho-S231 antibody
(Figure 5c). Interestingly, the phosphorylation of endogenous
human Par-4 site S231 increased in the resistant PC-3 cells
following TRAIL treatment (Figure 5c). To further study the
functionality of S231, we transfected the human cancer cell
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Figure 3 Phosphorylation of rodent Par-4 by CK2 blocks Par-4 proapoptotic functions. (a–c) PC-3 cells were transfected with empty GFP vector control (Mock), rat GFPtagged Par-4, GFP-tagged 124A223A mutant (mimicking non-phosphorylated Par-4 form) or 124D223D mutant (mimicking phosphorylated Par-4 form) and then treated with
recombinant death ligand TRAIL (500 ng/ml, 3 h). (a) Green fluorescent (transfected) cells were gated (represent around 20% of total cell) and further analyzed for apoptosis
by Hoechst staining. Bars represent the mean±S.D. of at least four independent experiments. (b) FACS analysis of the caspase-3 activity was assessed by red fluorescent
signal FLICA (Fluorogenic inhibitors of caspase-3 activation). Bars represent the mean±S.D. of at least four independent experiments. (c) Immunoblot analysis of caspase-8
and PARP cleavage (included both GFP-positive and -negative cells) at the indicated times. *Po0.05, **Po0.01. (d) PC-3 cells, transfected as above, were treated 8 h with
200 nM of Paclitaxel, and then apoptosis was determined by detection of caspases 8 and PARP cleavage. Hsp90 and 14-3-3 were used as a loading control

line HCT116, which allowed high transfection efficiency, with
the S231D and S231A Par-4 mutants and determined their
effect on apoptosis. The cells transfected with the S231A
mutant showed enhanced sensitivity to TRAIL, as judged by
caspase-8, PARP cleavage and DAPI staining. Conversely,
cells transfected with the constitutively phosphorylated
S231D mutant were less sensitive to TRAIL (Figures 5d–f).
These results indicate that phosphorylation by CK2 at
residue S231 of human Par-4 strongly impairs Par-4
apoptotic properties and seems to be more efficient than the
phospho mimicking mutant S223D of rat Par-4
(Supplementary Figure S7).
Par-4 phosphorylation by CK2 in prostate cancer cells.
CK2 activity is elevated in prostate cancer cells compared
with their normal counterparts.35 Therefore, we assessed by
immunoblotting the phosphorylation status of Par-4, in
parallel with CK2 expression and activity, in human prostate
cancer cells (PC-3, LNCaP) versus normal cells (PNT2C2,
PrEC) (Figure 6a). Our results revealed that Par-4 phosphorylation at the CK2 site S231 occurs preferentially in
cancer cells, which display a higher CK2 activity compared
with normal cells. Accordingly, the CK2 protein level is
increased in prostate cancer (especially the CK2b subunit)
as compared with their normal counterparts (Figure 6a).
Furthermore, CK2 depletion in PC-3 cells by siRNA
significantly impaired Par-4 phosphorylation at S231
(Figure 6b). Accordingly, we noted a coordinated regulation
of CK2a protein levels and Par-4 phosphorylation, that is,
both showed approximately 50% decrease (Figure 6b).
Similar results were obtained using the selective inhibitor of
Cell Death and Disease

CK2, 4,5,6 tetrabromobenzotriazole (TBB; Supplementary
Figure S9).47,48
As previously reported,43,49–51 CK2-depleted cells are more
sensitive to apoptosis. In line with these results, resistant PC-3
cells were more sensitive to TRAIL treatment when they were
transfected with two different CK2 siRNA (siCK2T and
siCK2AB, Figures 7a–d and Supplementary Figure S10).
Most importantly, when we co-depleted CK2 and Par-4 by
siRNA (two different siRNAs tested for each), we restored PC-3
cell resistance to TRAIL-induced apoptosis (Figures 7a–d and
Supplementary Figure S10). Collectively, these results
suggest that CK2 anti-apoptotic effect involves Par-4 phosphorylation and inhibition of Par-4 proapoptotic functions.
Discussion
Par-4 induces tumor regression in prostate tumors, and this
action is associated with both Par-4 intracellular and extracellular proapoptotic functions. Indeed, Par-4 has been shown
to be secreted and to induce apoptosis in the surrounding
cells.26 In this study, we noted both in rat and human that:
(i) Par-4 is a new substrate of the survival kinase CK2, and
(ii) phosphorylation by CK2 impairs Par-4 proapoptotic
functions (hypothetical model, Supplementary Figure S11).
We also unraveled another level of CK2-dependent
regulation of Par-4 apoptotic functions. Cleavage of Par-4
by caspases is a crucial step that leads to the production of a
Par-4-cleaved form ((132–340) in humans and (124–332) in
rats) that displays full apoptotic activity. Phosphorylation of rat
Par-4 at S124 by CK2 inhibits caspase-mediated cleavage at
residue D123, thus dramatically reducing its apoptotic
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Figure 4 Rodent Par-4 phosphorylation by CK2 prevents caspase-mediated Par-4 cleavage. (a) PC-3 cells transfected with the GFP-tagged constructs wild-type rat
Par-4, 124A/D, 223A/D, 124A223A or 124D223D mutants of Par-4 were treated with TRAIL (500 ng/ml, 3 h) in the presence or absence of Z-VAD (15 mM). Par-4 cleavage was
determined by western blotting using anti-GFP antibody. Hsp90 was used as a loading control. (b) Wild-type Par-4, 124A/D, 223A/D, 124D223D and 124A223A mutant
proteins (GFP tagged) were produced in vitro by a TNT RRL system. Recombinant caspase-8 (upper panel) or caspase-3 and -7 (Casp3, Casp7, lower panel) were incubated
with the indicated Par-4 proteins for 3 h at 37 1C, and Par-4 cleavage was assessed by western blotting using GFP antibody. (c) Caspase assay was performed on prephosphorylated rat GST-Par-4 (in vitro kinase assay using RecCK2 as described above Figure 2), and cleaved Par-4 was detected by immunoblot. *NS: non-specific bands
are probably due to the presence of recombinant Par-4 degraded forms. To note: cleaved GST Par-4 migrates at lower molecular weight than cleaved GFP-Par-4, given GST
tag is located in the N-terminus of Par-4 and not on C-terminus as the GFP-tag. (d–f) PC-3 cells transfected with Par-4 wild-type or FLAG-tagged Par-4 (124–332) were treated
as above with TRAIL and analyzed for apoptosis by Hoechst staining (d) or FACS analysis of the caspase-3 activity (FLICA) (e) and by immunoblotting analysis of caspase-8
and PARP cleavage (f). Bars represent the mean±S.D. of at least three independent experiments. Flag-Par-4 (124–332) and GFP were revealed in the same membrane
using corresponding antibodies (lower panel). Endogenous Par-4 was used as a loading control. *Po0.05, **Po0.01

function. Notably, this inhibitory effect of CK2 on Par-4
cleavage occurs in rat Par-4 but not in human Par-4,
underlying species-specific effects of CK2 phosphorylation.
Similarly to rat Par-4, the proteolytic cleavage of caspase-9 is
specifically blocked in rodent cells by CK2 phosphorylation.52
In both species, caspase-dependent cleavage of other
substrates such as Bid, Max or apoptosis repressor with
caspase recruitment domain, has been also shown to be
blocked by CK2 phosphorylation.40,53 In the case of Bid,
phosphorylation by CK2 prevents the generation of a Bid
caspase-cleaved form that, as for Par-4, is active and can

induce apoptosis. Therefore, CK2 is able to inhibit the activity
of its substrates across species, yet by acting through
different mechanisms in a species-dependent manner.
The caspase-cleavage product of Par-4 is also
secreted and induces a ‘bystander’ effect that results
in the killing of the surrounding cells (Supplementary
Figure S8), which might create an amplification loop in
cell apoptotic process. The proapoptotic effect of the rat
Par-4 cleaved form (124–332), as for human Par-4,
likely relies on the presence of the SAC domain that is an
essential domain for extracellular and intracellular Par-4
Cell Death and Disease
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Figure 5 Human Par-4 is phosphorylated both in vitro and in vivo on S231 (ortholog of rodent S223) by CK2 and this phosphorylation impairs apoptosis. (a) Conservation
of the CK2 recognition motif (including the serine 231 of human Par-4) was evaluated in different species. (b) Recombinant Myc-tagged human Par-4 (hPar-4) or 231D mutant
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using Myc antibody, and apoptosis was monitored by immunoblot analysis of caspase-8 and PARP cleavage (d) and by DAPI staining (e and f). Bar graph shows semiquantified densitometry from PARP and Caspase-8 western blotting analysis. Bars represent the mean±S.D. of at least four independent experiments. Hsp90 was used as a
loading control. Bar ¼ 10 mm, magnification  63; *Po0.05. a.u, arbitrary unit

proapoptotic activity.21,26 In contrast, the N-terminal rat
Par-4 truncated form (1–163) is devoid of proapoptotic
function.10,21
In this work, we observed that S231D mutant of human
Par-4 is weakly phosphorylated by CK2, thus suggesting that
although this is the major phosphosite for CK2 other minor
Cell Death and Disease

phosphorylation sites are present. Among the potential sites,
residues S233 and S110 deserve further considerations.
However, we have demonstrated the essential regulatory
function of residue S231, via its ability to impair the
proapoptotic function of human Par-4 following phosphorylation by CK2. Consistently, CK2 knockdown is associated with
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Figure 6 Par-4 is highly phosphorylated on S231 (ortholog of rodent S223) in
human prostate cancer cells compared with normal counterparts. (a) Upper panel,
phosphorylation of Par-4 on S231 was studied by western blotting in prostate cancer
cells (PC-3, LnCap cells) and in normal prostate cells (PrCE, PNT2C2). In parallel,
endogenous expression of Par-4 and CK2 subunits in the different cell lines was
determined (middle panel). Hsp90 was used as a loading control. Lower panel,
analysis of CK2 activity in the different prostate cells studied using Cyclex CK2
screening kit. Bars represent the mean±S.D. of at least two independent
experiments. (b) PC-3 cells were transfected with CK2 siRNA (siCK2T,
ThermoFischer) or scrambled siRNA fluorescently labeled with FAM (Scr siRNA)
for 48 h and then treated or not with TRAIL (500 ng/ml, 3 h). Endogenous
phosphorylated human Par-4 was detected by western blotting using the antiphospho231 Par-4 antibody (Ph231-hPar-4) (left panel). Par-4 expression (left
panel) and downregulation of CK2a protein (right panel) were evaluated by
immunoblotting using the corresponding antibodies. Bar graph shows semiquantified densitometry from western blotting analysis

diminished S231 phosphorylation, and this results in an
increased sensitivity to apoptosis. In contrast to phosphorylation of S124 in rat Par-4 protein, phosphorylation of S231 did
not affect human Par-4 cleavage by caspases. The mechanism by which phosphorylated S231 prevents Par-4-induced
apoptosis deserves further investigations. Because S231 is
located in the C-terminal domain of Par-4 – which mediates
interaction of Par-4 with its partners (i.e., NF-kB, PKCz) – we
hypothesize that S231 phosphorylation may prevent these

interactions. CK2 is known to be a partner of p6254 and
PKCz,55 and p62 prevents the inhibitory effect of Par-4 on
PKCz activity during apoptosis.56 During apoptosis, the p62CK2-PKCz-Par-4 complex may further increase the phosphorylation of Par-4 by CK2, leading to a strong inhibition of
Par-4 proapoptotic functions. Consistent with this hypothesis,
we observed an increase in human Par-4 phosphorylation
during TRAIL-induced apoptosis in the resistant PC-3 cancer
cells (Figure 5c). Importantly, S231 is highly phosphorylated
in human prostate cancer cells compared with normal cells,
thus suggesting that CK2 phosphorylated Par-4 could be a
potential biomarker of prostate cancer. Similar to other tumor
suppressors, such as phosphatase tensin homolog or
promyelocytic leukemia, Par-4 is a key CK2 target (this
paper), whose proapoptotic activity must be blocked to allow
tumor progression.18,19,20 This observation is consistent with
our findings indicating that increased sensitivity of PC-3 cells to
apoptosis following CK2 depletion is hampered by siRNAmediated Par-4 depletion. Several other observations support
the fact that the pro-tumorigenic function of CK2 may depend
on the inhibition of Par-4. First, the overexpression of Par-4, as
well as treatment with CK2 inhibitors, showed barely any effect
in normal cells, yet resulted in a potent induction of apoptosis in
cancer cells.49,57 Second, CK2 inhibitors were reported to
induce ER-mediated apoptosis, while ER stress favors Par-4
secretion and apoptosis.26 Third, CK2 antisense delivery into
prostate cancer xenografts or intra-tumor injection of a peptide
preventing CK2 phosphorylation, both associated with significant reduction of CK2 activity, demonstrated a potent
induction of apoptosis and tumor regression.51 A similar
induction of apoptosis and tumor regression of prostate cancer
is observed when Par-4 is injected intra-tumorally in nude
mice.1
In summary, our findings shed light on a new regulatory role
of CK2 on Par-4 functions in prostate cancer cells and
delineate Par-4 as a key target that could be exploited for the
development of anti-tumoral therapeutics in prostate cancer.

Materials and Methods
Cells and reagents. Human colon cancer HCT116, prostate cancer PC3,
LnCap cells and benign prostate PNT2C2 cells were cultured in RPMI 1640
(BioWittaker, Fontenay sous-bois, France) and PrEC cells in medium Bullet kit
(Lonza, Walkersville, USA). The authentication of cell lines was conducted by
ATCC (Molsheim, France). COS7 cells were grown in Dubelcco’s Modified Eagle
Medium (BioWittaker). The selective inhibitor of CK2, TBB (Sigma-Aldrich, St
Quentin Fallavier, France) was pre-incubated for 30 min and used at 20 or 40 mM.
The recombinant human His-TRAIL was produced as described previously.58
The pan caspase inhibitor zVAD-FMK and the phosphatase inhibitors Calyculin A
and Okadaic acid (Calbiochem and Merck KGaA, Darmstadt, Germany) were used
at 15 mM, 20 nM and 0.5 or 1 mM, respectively.
Plasmids and transfection. GST-Par-4 was a gift from Dr. Robert
(University of Manchester); GFP-CK2a and b constructs and their corresponding
mutants were previously described.59 The rat constructs pcDNA3.1 TOPO GFPPar-4 mutants (124A223A, 124D223D, 124A, 124D, 223A, 223D, 123A), the Flag
or GFP deletant rat Par-4 (124–332) and the human constructs pcDNA3.1 MycPar-4 (wild-type, 231A and 231D mutants) were performed by directed
mutagenesis following the manufacturer’s instructions (Stratagene, Agilent
Technology, Massy, France). Cell lines were transfected for 15 h (no significant
apoptosis due to Par-4 overexpression is detected at that time29 and data not
shown) using Nanojuice (Millipore, Molsheim, France) or Jetpei (Polyplustransfection, Ozyme, St Quentin en Yvelines, France). PC3 cells were transfected with
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Figure 7 Anti-apoptotic role of CK2 is dependent on Par-4 in human prostate cancer cells. (a–d) PC-3 cells were transfected with different CK2 siRNAs (siCK2T from
ThermoFischer (a) or siCK2AB from Ambion (b)) together with scrambled siRNA fluorescently labeled with FAM (Scr siRNA) or different Par-4 siRNA (siPar-4T from
ThermoFisher or siPar-4sc from Santa Cruz) for 48 h. Then, cells were treated or not with TRAIL (500 ng/ml, 3 h). The downregulation of Par-4 and CK2a proteins was
confirmed by immunoblot using the corresponding antibodies. Apoptosis was monitored (a and b) by immunoblot analysis of caspase-8 and PARP (long and short cleaved
PARP forms) cleavage and (c and d) by DAPI staining. Graphs represent semi-quantified densitometry analysis from PARP and caspase-8 western blotting analysis of panel (a).
See also Supplementary Figure S10A for the densitometric analysis of panel (b). Bars represent the mean±S.D. of at least four independent experiments. Hsp90 was used as a
loading control. Bar ¼ 10 mm, magnification  63; *Po0.05. a.u, arbitrary unit

interferin reagent using two different human CK2 siRNA (siCK2T (L-003475-000005) ON-TARGETplus SMARTpool from Thermo Fisher Scientific (Waltham, MA,
USA) or siCK2AB from Ambion (Life Technology, Saint Aubin, France, S3638))
and/or two different human Par-4 siRNA (siPar-4T (L-004434-00-0005) ONTARGETplus SMARTpool from Thermo Fisher Scientific (or siPar-4sc (SC-36190)
from Santa Cruz (Tebu-Bio, Le Perray en Yveline, France)) together with
scrambled siRNA fluorescently labeled with FAM (Scr siRNA, Santa Cruz) for 48 h.
Recombinant protein purification. Escherichia coli BL21 bacteria
expressing GST-Par-4 were grown 3 h with 1 mM isopropyl b-D-1-thiogalactopyranoside. After centrifugation at 5000  g for 10 min, bacteria were lysed in 50 mM
Tris-HCl pH 8, 300 mM sodium chloride (NaCl), 1% triton, 0.2 mM EDTA, 1 mM
dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF) and protease inhibitors
for 30 min. Gluthatione sepharose 4B beads (Sigma, Saint-Quentin Fallavier, France)
Cell Death and Disease

were added to the cleared supernatants and subjected to rotation for 30 min at
4 1C. Beads were washed four times in phosphate-buffered saline, 1 mM DTT and
1 mM PMSF, and the recombinant protein was eluted in 50 mM Tris-HCl, 0.3%
Triton, 20 mM NaCl, 50 mM Glutathione, 1 mM DTT for 15 min at 4 1C with
agitation. The protein concentration was evaluated using the Bradford method.
Proteins using TNT Quick Coupled Transcription/Transcription System
(Promega, Charbonnières-les-Bains, France) were produced as follows: 1 mg of
template plasmid DNA was added to the reaction mixture, which was afterwards
incubated at 30 1C for 90 min. Twenty microliters of the in vitro translated proteins
were used for immunoprecipitation.
Immunoprecipitation and immunoblotting. Cells were lysed in lysis
buffer (50 mM Hepes pH 7.4, 140 mM NaCl, 5 mM EDTA, 0.2% NP40, 10 mM
sodium fluoride, protease inhibitor cocktail (Roche, Neuilly sur Seine, France)). In all,
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800 mg of each lysate was incubated with 3 mg of CK2a, CK2b (Santa Cruz), Par-4
(Sigma-Aldrich), GFP-tag (Millipore) or HA-tag (Biomol, Hamburg, Germany)
antibodies with constant agitation at 4 1C. Then, the immuno-complexes were
precipitated with protein G (Amersham Bioscience, GE Healthcare, Orsay, France),
and the beads were washed in lysis buffer and resuspended in Laemmli buffer.
Proteins were separated on SDS-PAGE 8–10%. The membranes were probed
with primary antibodies and then incubated with the appropriate secondary
antibody. Proteins were visualized using the ECL western blotting kit (Pierce,
ThermoScientific, Rockford, IL, USA). The rabbit anti-Par-4 was purchased from
Sigma-Aldrich, the mouse CK2b, rabbit anti-14-3-3t and -actin antibodies were
from Santa Cruz and the mouse anti-CK2a was purchased from Millipore. The
monoclonal Myc-tag antibody and the polyclonal rabbit antibodies anti-PP1 and GST were purchased from Cell Signaling (Danvers, MA, USA). The rabbit antihuman phospho-serine 231 Par-4 antibody was produced by Covalab (Dijon,
France). Hsp90, Hsp110 were from Stressgen (Tebu-Bio).
Luciferase assay. Cos cells were transfected with the different Par-4 mutants
in the presence or absence of the NF-kB promoter and Beta galactosidase (Gift
from Professor L Sistonen, Finland) as an internal control. Cells were lysed 24 h
post transfection and, after dosage, assayed using Promega’s Luciferase Assay
System kit (Promega, Charbonnières-les-Bains, France). Luciferase activity was
measured using a Luminometer (Promega, Mannheim, Germany, LUMAT LB
9507). To normalize for transfection efficiency, the activity of co-transfected
b-galactosidase was also assayed.
Caspase cleavage assay. In vitro translated Par-4 protein and the
corresponding mutants were produced using TNT Quick Coupled Transcription
System (Promega, Charbonnières-les-Bains, France). Fourmicroliters of the in vitro
translated proteins were incubated for 3 h with one unit of recombinant caspases 8,
3 and 7 (R&D System, Lille, France) in a buffer containing 10 mg CHAPS, 25 mM
Hepes (pH 7.4), 10 mM DTT.
In vitro kinase assay. Immunoprecipitated GFP-CK2 from Cos cells or 60 ng
of recombinant CK2 (RecCK2) (New England Biolabs, Evry, France) was added in
the kinase reaction buffer (20 mM Hepes pH 7.4, 1 mM DTT, 10 mM magnesium
chloride, 10 mM MnCl2, 0.2 mM EGTA) containing 200 mM adenosine triphosphate
(ATP), 10 mCi [g32P] ATP in the presence of 5 mg of purified rat GST-Par-4 or the
immunoprecipitated recombinant rat wild-type GFP-tagged Par-4 and its corresponding mutants (124A223A, 124A, 223A) or the immunoprecipitated recombinant human
GFP- or Myc-tagged wild-type Par-4 and its corresponding mutant (Myc-231A), all
produced by in vitro translation as described above. After incubation (25 min, 30 1C),
Laemmli buffer was added to stop the reaction, and the samples were resolved on
10% SDS-PAGE gels. The phosphorylated Par-4 protein was visualized by staining
with Coomassie blue, and the dried gel was exposed to autoradiography.

8 cleavage by western blotting using anti-mouse caspase-8 from R&D and rabbit
PARP (detection of the short cleaved form) or mouse PARP (detection of the large
fragment) antibodies (Santa Cruz).
For FACS analysis, cells stained with APO and FITC–annexin V conjugate were
analyzed by flow cytometry using a FACS Scan flow cytometer (Becton Dickinson,
Franklin Lakes, NJ, USA). Caspase-3 activity was measured by FACS using the
fluorochrome benzyloxycarbonyl-Asp-Glu-Val-Asp (OMe) fluoromethylketone (PromoKine Caspase-3 kit, PromoCell, Heidelberg, Germany).
Tryptic digestion, two-dimensional separation and Edman
degradation. In-gel tryptic digestions of 32P-labeled Par-4 followed by a
two-dimensional phosphopeptide mapping were carried out as previously
described.60 Briefly, the labeled Par-4 band was excised from the dried gel and
in-gel digested with sequencing grade trypsin (Promega, Mannheim, Germany).
The gel pieces were incubated with 2 ng/ml trypsin in 50 mM ammonium
bicarbonate buffer (pH 8) for 16 h at 37 1C. Supernatants were collected, vacuumdried and resuspended in 15 ml of pH 1.9 buffer (formic acid 2.3%, acetic acid
2.9% v/v). Peptides were then separated in two dimensions by electrophoresis and
TLC. The first dimension – electrophoresis – was performed in a pH 1.9 buffer at
750 V for 1.5 h using the Hunter Thin Layer Peptide Mapping System, model no.
HTLE-7000 (C.B.S. Scientific). Fifteenmicroliters of the tryptic digest together with
the 3 ml of separation markers mixture (Xylene Cyanol FF (blue), 1 mg/ml and NeDNP-L lysine hydrochloride (yellow), 5 mg/ml, Sigma) were carefully applied on a
cellulose sheet (20  20 cm2, Merck KgaA) and electrophoretically separated. The
sheet was dried and ascending TLC in the second dimension was performed for
13 h in a chromatography tank saturated with a mobile phase containing 30%
water, 37.5% nbutanol, 7.5% acetic acid and 25% pyridine. The sheet was dried
and the 32P-phosphopeptides were visualized by autoradiography. For MALDI MS
and Edman sequencing, corresponding 32P-peptides were extracted from a
cellulose sheet by scraping off the powder into an Eppendorf tube and then eluted
twice with 200 ml of 30% acetonitrile (Rathbrun, UN1648) and 0.1% trifluoroacetic
(Sigma-aldrich) solution. The resulting extract was vacuum-evaporated, and
MALDI-MS was performed. For Edman degradation, phosphopeptides were
immobilized on arylamine membrane discs (Sequelon-AA membrane; Applied
Biosystems, Foster City, CA, USA) using water-soluble carbodiimide. The
Sequelon-AA membranes consist of a PVDF matrix that has been derivatized with
arylamine groups. Individual Par-4 phosphopeptides are immobilized on the
Sequelon-AA discs through their C-terminal carboxyl groups. Therefore, the N
termini of such peptides are free, and amino acids are clipped off during 10 Edman
degradation cycles. The collected fractions were spotted on a Whatman filter
paper, which was then visualized by autoradiography on a Fuji phosphorimager
plate (VWR International Oy, Helsinki, Finland) to reveal the cycle at which the
radiolabel is released, which corresponds to the position of the phosphorylated
amino acid, as counted from the N-terminus.

Measure of CK2 activity. The determination of CK2 activity was performed
as described by the manufacturer (Cliniscience, Nanterre, France). Briefly, 10 mg
of cell lysate from the different prostate cell lines were diluted in the CK2 buffer in
the presence of ATP and incubated 30 min at 30 1C in a 96-well plate pre-coated
with the substrate corresponding to recombinant p53, which contains a serine
residue (S46) that was phosphorylated by CK2. After several washings, a specific
horseradish peroxidase (HRP)-conjugated antibody recognizing only the
phosphorylated serine 46 of p53 was added in each well for 30 min at room
temperature. Then, the amount of phosphorylated substrate was determined by
addition of the HRP substrate and measurement by spectrophotometry (dual
wavelength 450/595 nm). As a positive control, we used recombinant CK2
(Rec.CK2, 20 000 units), and as a baseline control samples treated with CK2specific inhibitor tetrabromocinnamic acid (20 mM, Calbiochem).

Statistical methods. Results are expressed as means±S.E.M. from at least
three independent experiments. Values were analyzed using the Student’s t-test.
All P-values were obtained using the two-tailed tests, and error bars in the graphs
represent 95% confidence intervals. Quantitative data were analyzed using the
GraphPad Prism program (La Jolla, CA, USA). Blots were treated by Photoshop
(San Jose, CA, USA) and quantified by Image J (Bethesda, MD, USA). Statistical
significance, Po0.05 and Po0.01, are denoted with single and double asterisks
(* and **), respectively.

Measure of apoptosis and caspase-3 activity. Cells transfected with
Par-4 mutants were either treated with recombinant His-TRAIL (500 ng/ml) or
Paclitaxel 200 nM (Calbiochem). Cells were harvested and fixed with 0.2%
paraformaldehyde in presence of 1 mg/ml of DAPI or Hoetsch 33342 (SigmaAldrich) to stain the nuclei. Apoptosis was measured by counting cells that are
condensed and fragmented. Images were acquired using the Cell Observer station
(Zeiss, Göttingen, Germany). Briefly, the system consists of an inverted
microscope AxioVert 200M (Zeiss) equipped for fluorescence with a CCD
camera. All the system is motorized and controlled by the Axiovision software
(Zeiss). Apoptosis was also assessed by the determination of PARP and caspase
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